Compare
Arvinas, Inc. vs Ligand Pharmaceuticals Inc vs Schrodinger, Inc. vs Harrow, Inc.
| Latest fiscal year | Arvinas, Inc. ARVN | Ligand Pharmaceuticals Inc LGND | Schrodinger, Inc. SDGR | Harrow, Inc. HROW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $262.60M | $268.09M | $255.87M | $272.30M |
| Revenue growth (YoY) | -0.3% | +60.4% | +23.3% | +36.4% |
| Gross margin | n/a | n/a | 55.7% | 75.1% |
| Operating margin | -45.1% | 15.3% | -65.2% | 11.2% |
| Net margin | -30.8% | 46.4% | -40.4% | -1.9% |
| Net income | -$80.80M | $124.45M | -$103.27M | -$5.14M |
| EPS (Diluted) | -$1.14 | $6.13 | -$1.41 | -$0.14 |
| Operating cash flow | -$273.80M | $49.36M | $13.90M | $43.86M |
| Free cash flow | -$275.70M | $48.91M | $12.46M | $42.98M |
| Cash & equivalents | $142.90M | $174.93M | $230.52M | $72.93M |
| Total assets | $717.90M | $1.56B | $726.16M | $399.48M |
| Total liabilities | $284.00M | $543.42M | $362.11M | $347.39M |
| Shareholders' equity | $433.90M | $1.02B | $364.05M | $52.45M |
| Return on year-end equity | -18.6% | 12.2% | -28.4% | -9.8% |
| Shares outstanding | 63.50M | 19.77M | n/a | 37.23M |
Revenue, most recent five fiscal years
| Fiscal year | Arvinas, Inc. | Ligand Pharmaceuticals Inc | Schrodinger, Inc. | Harrow, Inc. |
|---|---|---|---|---|
| Latest | $262.60M Ended 2025-12-31 | $268.09M Ended 2025-12-31 | $255.87M Ended 2025-12-31 | $272.30M Ended 2025-12-31 |
| 1 year earlier | $263.40M Ended 2024-12-31 | $167.13M Ended 2024-12-31 | $207.54M Ended 2024-12-31 | $199.61M Ended 2024-12-31 |
| 2 years earlier | $78.50M Ended 2023-12-31 | $131.31M Ended 2023-12-31 | $216.67M Ended 2023-12-31 | $130.19M Ended 2023-12-31 |
| 3 years earlier | $131.40M Ended 2022-12-31 | $196.25M Ended 2022-12-31 | $180.96M Ended 2022-12-31 | $88.59M Ended 2022-12-31 |
| 4 years earlier | $53.60M Ended 2021-12-31 | $241.54M Ended 2021-12-31 | $137.93M Ended 2021-12-31 | $72.48M Ended 2021-12-31 |